TG Therapeutics Inc (TGTX)

Working capital turnover

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	US$ in thousands	221,047	2,785	6,689	152	152
Total current assets	US$ in thousands	317,943	168,274	330,965	611,740	149,151
Total current liabilities	US$ in thousands	53,720	53,201	65,384	87,554	84,449
Working capital turnover		0.84	0.02	0.03	0.00	0.00

December 31, 2023 calculation

Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $221,047K ÷ ($317,943K – $53,720K)
= 0.84

TG Therapeutics Inc's working capital turnover has shown significant improvement over the past five years. The ratio increased from 0.00 in 2019 to 0.84 in 2023, indicating a more efficient utilization of working capital to generate revenue. This upward trend suggests that the company has been able to better manage its current assets and liabilities to support its operations. However, it's worth noting the sharp increase from 2022 to 2023 which may warrant further investigation to understand the reasons behind such a significant jump and ensure the sustainability of this improved performance. Overall, the increasing working capital turnover ratio reflects positively on TG Therapeutics Inc's operational efficiency and financial health.